Advertisement

Search Results

Advertisement



Your search for all items matches 32603 pages

Showing 151 - 200


pancreatic cancer

Frank Kullmann, MD, on Metastatic Pancreatic Cancer: Recent Data on Gemcitabine and Nab-Paclitaxel

Frank Kullmann, MD, of Germany’s Klinikum Weiden, discusses results from the ALPACA trial, which suggest a dose-reduced regimen with alternating cycles of gemcitabine/nab-paclitaxel and gemcitabine monotherapy after three induction cycles of standard gemcitabine/nab-paclitaxel is feasible and...

gastroesophageal cancer

Manish A. Shah, MD, on Esophageal Cancer: Long-Term Outcomes of Pembrolizumab and Chemotherapy

Manish A. Shah, MD, of Weill Cornell Medical College, discusses phase III findings of the KEYNOTE-590 study, which shows that, after 5 years, the use of pembrolizumab plus chemotherapy improved survival with durable efficacy, compared with placebo plus chemotherapy, in patients with untreated...

leukemia

Intensified vs Standard Induction in Younger Patients With Newly Diagnosed AML

In a UK trial (NCRI AML19) reported in the Journal of Clinical Oncology, Russell et al found that intensified induction therapy with FLAG-Ida (fludarabine, cytarabine, granulocyte colony–stimulating factor, and idarubicin) plus gemtuzumab ozogamicin did not improve overall survival in younger...

lung cancer

Rate of Second Primary Lung Cancers With Lobar vs Sublobar Resection of T1aN0 NSCLC

As reported in the Journal of Clinical Oncology by Thomas E. Stinchcombe, MD, and colleagues, an analysis from the phase III Cancer and Leukemia Group B 140503/Alliance trial has shown high rates of second primary lung cancers with both sublobar and lobar resections for T1aN0 non–small cell lung...

Expert Point of View: Harry P. Erba, MD, PhD

Harry P. Erba, MD, PhD, Professor of Medicine and Director of the Leukemia Program in the Division of Hematologic Malignancies and Cellular Therapy at Duke University School of Medicine, Durham, North Carolina, told The ASCO Post he was not surprised by one of the key findings reported by Smith et ...

leukemia

Study Examines Real-World Outcomes With Ivosidenib vs Venetoclax in Acute Myeloid Leukemia

In a comparison of real-world outcomes for two common first-line regimens for acute myeloid leukemia (AML) with mutations in isocitrate dehydrogenase 1 (IDH1), treatment with the IDH1-targeted agent ivosidenib plus a hypomethylating agent was associated with better outcomes than venetoclax plus a...

prostate cancer

Cabozantinib and Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

Patients with metastatic castration-resistant prostate cancer with extrapelvic nodal or visceral metastasis who were treated with the combination of cabozantinib plus atezolizumab had significantly improved time to disease progression compared with those who were treated with hormonal therapy. This ...

supportive care
survivorship

Study Finds Plant-Rich Foods, Nuts/Seeds May Benefit Childhood Cancer Survivors

A recent study, published by Wang et al in the Journal of Clinical Oncology, conducted as part of the St. Jude Lifetime Cohort (SJLIFE), may provide new insights into how diet may affect aging in adult survivors of childhood cancer. This study, involving 3,322 participants aged 18 to 65, found that ...

solid tumors
hematologic malignancies
issues in oncology

Unintentional Weight Loss May Be a Warning Sign of Cancer, Study Finds

Unintentional weight loss may be associated with an increased risk of receiving a cancer diagnosis within the next year, according to a recent study published by Wang et al in JAMA. Background Patients with advanced cancer often experience weight loss. However, weight loss is often not thought to...

issues in oncology

Generic Drug Shortages and Essential Cancer Medicines

Decisions regarding the rationing of chemotherapy are commonplace in many countries around the world—including those where patients must pay for chemotherapy out of pocket—and increasingly so in cancer settings that treat both well-off and socioeconomically disadvantaged patients. However, these...

2023 ASCO Advocacy Highlights

The Association for Clinical Oncology (ASCO) had an immensely impactful year of advocacy work, which is possible only with guidance and passion from our members. In partnership with the ASCO’s Government Relations Committee, five advocacy priorities were identified for the year: Protecting...

gynecologic cancers

OVHIPEC-1 Trial: Hyperthermic Intraperitoneal Chemotherapy Plus Interval Cytoreductive Surgery Improves Survival in Advanced Ovarian Cancer

The final survival analysis of the Dutch-Belgian phase III OVHIPEC-1 trial showed that the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery was associated with maintained progression-free and overall survival benefits at 10 years in women with advanced ...

cardio-oncology

International Collaborative Research Efforts in Cardio-Oncology

At the 2023 Global Cardio-Oncology Symposium (GCOS), international experts explored the ongoing collaborative efforts to improve the cardiovascular health of patients being treated for cancer as well as the bidirectional challenges of translating basic research to clinical care. Focus on Basic and...

supportive care
integrative oncology

Expert Point of View: Daniel Curtis McFarland, DO, MS

Invited discussant of the abstracts on the virtual mind-body fitness program and the BRIDGE intervention from the 2023 ASCO Quality Care Symposium, Daniel Curtis McFarland, DO, MS, of Wilmot Cancer Center, University of Rochester Medical Center, New York, said they highlight the unmet need...

supportive care
integrative oncology

Integrated Medicine and Collaborative Care: Innovations in Cancer Treatment and Mental Health Care

Recent studies by multidisciplinary teams at Memorial Sloan Kettering Cancer Center and Massachusetts General Hospital are illuminating novel ways to address health-care challenges faced by patients with cancer. The research, presented at the 2023 ASCO Quality Care Symposium, highlights the...

breast cancer

Expert Point of View: Laura Huppert, MD

Invited discussant Laura Huppert, MD, of the University of California, San Francisco, Comprehensive Cancer Center, focused her remarks on the need for biomarkers for selection of immunotherapy as part of neoadjuvant chemotherapy for hormone receptor–positive, HER2-negative breast cancer. “Hormone...

breast cancer

Neoadjuvant Chemoimmunotherapy Improves Pathologic Complete Response Rates in Subgroup Analysis of KEYNOTE-756

Pembrolizumab added to neoadjuvant chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy improved pathologic complete responses in patients with early-stage, high-risk, estrogen receptor (ER)-positive, HER2-negative breast cancer, according to updated results of the phase III...

breast cancer

Expert Point of View: Heather Han, MD

Heather Han, MD, Research Director, Department of Breast Oncology, Moffitt Cancer Center, Tampa, commented on the latest update from the NATALEE trial: “Despite the established standard adjuvant therapy, many patients with hormone receptor–positive, early-stage breast cancer (including stages...

breast cancer

NATALEE Trial: Long-Term Results on Ribociclib Combination Therapy in Early-Stage Breast Cancer

Invasive disease–free survival continued to be significantly improved for patients with hormone receptor–positive, HER2-negative, early-stage breast cancer who received the CDK4/6 inhibitor ribociclib plus a nonsteroidal aromatase inhibitor compared with a nonsteroidal aromatase inhibitor alone....

multiple myeloma

Expert Point of View: Cynthia E. Dunbar, MD

In a press briefing at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, Cynthia E. Dunbar, MD, ASH Secretary and Chief of the Translational Stem Cell Biology Branch, Intramural Research Program of the National Heart, Lung, and Blood Institute, offered her thoughts on...

multiple myeloma

Canadian Study Shows Myeloma Outcomes in the Real World May Be Worse Than Clinical Trials Suggest

Patients with multiple myeloma treated in the “real world” had worse outcomes than patients who received the same treatment on clinical trials, according to research presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition.1 In a pooled analysis of clinical trial...

lymphoma

Expert Point of View: Andrew D. Zelenetz, MD, PhD

Andrew D. Zelenetz, MD, PhD, Medical Director of Quality Informatics at Memorial Sloan Kettering Cancer Center, New York, offered his thoughts on the combination of venetoclax and ibrutinib in the treatment of mantle cell lymphoma, as presented at the 2023 American Society of Hematology (ASH)...

lymphoma

SYMPATICO Trial: Ibrutinib Plus Venetoclax Improves Progression-Free Survival in Relapsed Mantle Cell Lymphoma

The combination of ibrutinib and venetoclax has led to an improved progression-free survival rate in patients with relapsed or refractory mantle cell lymphoma (MCL), according to findings presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Interim analysis...

leukemia

Expert Point of View: Paul J. Hampel, MD

Paul J. Hampel, MD, a hematologist/oncologist at Mayo Clinic, Rochester, Minnesota, underscored the complexity of this arm of the adaptive FLAIR trial, which compared measurable residual disease (MRD)-directed ibrutinib plus venetoclax with standard, fixed-duration, FCR (fludarabine,...

leukemia

Personalized Ibrutinib-Plus-Venetoclax Therapy: New Treatment Standard for Chronic Lymphocytic Leukemia?

A time-limited approach based on measurable residual disease (MRD) response could signal a potential paradigm shift for front-line treatment of chronic lymphocytic leukemia (CLL), according to data presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition1 and...

multiple myeloma

Expert Point of View: Ajay K. Nooka, MD, MPH, and Dan Vogl, MD, MSCE

Ajay K. Nooka, MD, MPH, Professor in the Department of Hematology and Medical Oncology at Emory University, and Dan Vogl, MD, MSCE, Associate Professor of Medicine at the Hospital of the University of Pennsylvania, shared their thoughts on the PERSEUS trial for The ASCO Post. Dr. Nooka noted that ...

multiple myeloma

Real-World Experience Mirrors PERSEUS Findings

At the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, researchers from Emory University presented a real-world comparison of the largest cohort of patients with newly diagnosed multiple myeloma consecutively treated with either bortezomib, lenalidomide, and dexamethasone ...

multiple myeloma

PERSEUS: Daratumumab Regimen Significantly Improves Progression-Free Survival in Newly Diagnosed Multiple Myeloma

The addition of the CD38 monoclonal antibody daratumumab to a standard regimen for patients with newly diagnosed transplant-­eligible multiple myeloma significantly prolonged progression-free survival vs standard treatment in the phase III PERSEUS trial. The study was reported as a late-breaking...

First-Line Therapy and Disease Progression in Metastatic ROS1-Positive NSCLC

This is Part 3 of Clinical Considerations in the Treatment of Metastatic ROS1 Fusion–Positive NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable.   In this video, Drs. Narjust Florez, Christine Bestvina, and Debora Bruno discuss first-line...

Management of CNS Metastases in ROS1-Positive NSCLC

This is Part 2 of Clinical Considerations in the Treatment of Metastatic ROS1 Fusion–Positive NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable.   In this video, Drs. Narjust Florez, Christine Bestvina, and Debora Bruno discuss the management of ...

Newly Diagnosed Metastatic ROS1-Positive NSCLC

This is Part 1 of Clinical Considerations in the Treatment of Metastatic ROS1 Fusion–Positive NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable.   In this video, Drs. Narjust Florez, Christine Bestvina, and Debora Bruno discuss the management of ...

gastroesophageal cancer

Ian Chau, MD, on Esophageal Squamous Cell Carcinoma: New Data on Nivolumab, Ipilimumab, and Chemotherapy

Ian Chau, MD, of The Royal Marsden Hospital, discusses an analysis from the CheckMate 648 study on quality-adjusted time without symptoms and toxicity in patients with unresectable advanced esophageal squamous cell carcinoma. Patients treated with nivolumab plus ipilimumab and nivolumab plus...

gastroesophageal cancer
gastrointestinal cancer

Additional Analysis of MATTERHORN Confirms Global Benefit of Durvalumab Plus FLOT in Gastric/Gastroesophageal Junction Cancer

Subgroup analyses of the randomized double-blind phase III MATTERHORN trial continue to show the benefit of adding perioperative durvalumab to standard chemotherapy in patients with locally advanced, resectable gastric or gastroesophageal junction cancer. Detailed findings on pathologic complete...

cardio-oncology

Use of Direct Oral Anticoagulant Agents in Active Cancer: Meta-Analysis

In a systematic review and meta-analysis reported in JACC: CardioOncology, Fujisaki et al found no significant differences among direct oral anticoagulant agents (DOACs) in the prevention of recurrent venous thromboembolism (VTE) associated with active cancer, whereas significant differences in...

pancreatic cancer

Gemcitabine/Paclitaxel vs Gemcitabine Alone After FOLFIRINOX in Metastatic Pancreatic Cancer

As reported in the Journal of Clinical Oncology by De La Fouchardière et al, the French phase III GEMPAX trial showed no overall survival benefit with second-line gemcitabine/paclitaxel vs gemcitabine alone after FOLFIRINOX (fluorouracil, oxaliplatin, and irinotecan) in patients with metastatic...

issues in oncology
immunotherapy

FDA Issues Safety Labeling Change Notification to CAR T-Cell Therapy Manufacturers

On January 19, the U.S. Food and Drug Administration (FDA) issued safety labeling change notification letters to all manufacturers of licensed B-cell maturation antigen (BCMA)-directed and CD19-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell immunotherapies requiring ...

skin cancer
issues in oncology

Melanoma Overdiagnoses May Be Rising Among White U.S. Patients

Over 50% of all melanoma diagnoses among White patients in the United States may in fact be overdiagnoses, according to a recent study published by Adamson et al in BMJ Evidence-Based Medicine. Background “Cases of cutaneous melanoma have risen significantly in the [United States] over the last 40...

colorectal cancer
supportive care

Study Finds Majority of Patients With Lynch Syndrome Are Not Using Aspirin to Reduce Risk of Colon Cancer

Investigators have found that only a minority of patients with Lynch syndrome may be receiving aspirin as chemopreventive therapy, according to new findings presented by Singhal et al at the 2024 ASCO Gastrointestinal Cancers Symposium (Abstract 19). Background “[Patients] with Lynch syndrome are...

George D. Demetri, MD, FASCO, Earns Lifetime Achievement Award in Medicine From Stanford Medicine Alumni Association

George D. Demetri, MD, FASCO, Director of the Sarcoma Center at Dana-Farber Cancer Institute, was awarded the J.E. Wallace Sterling Lifetime Achievement Award in Medicine from the Stanford Medicine Alumni Association (SMAA). Dr. Demetri, an alumnus of the Stanford University School of Medicine,...

breast cancer

My Breast Cancer Experience Has Led Me to Leverage My Expertise in Human-Centered Design to Transform Patient Care

The road to my breast cancer diagnosis in 2018 was long and tortuous. For 3 years leading up to the diagnosis, I had imaging scans and tissue biopsies every 3 months because of suspicious masses in my breasts. The uncertainty was so destabilizing that I was in a constant state of emotional unrest....

prostate cancer

Use of Enzalutamide in Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence

On November 16, 2023, the androgen receptor inhibitor enzalutamide was approved for use in patients with nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.1 Supporting Efficacy Data Approval was based on the EMBARK trial (ClinicalTrials.gov...

multiple myeloma

The High Cost of Oral Agents for Relapsed and Refractory Multiple Myeloma

Late in 2023, Richardson et al shared the results of a phase I/II clinical trial (ClinicalTrials.gov identifier NCT03374085). They concluded that the “all-oral combination of mezigdomide plus dexamethasone showed promising efficacy in patients with heavily pretreated multiple myeloma.”1 Mezigdomide ...

gastroesophageal cancer

Ken Kato, MD, PhD, on Advanced Esophageal Cancer: Biomarker Analyses From CheckMate 648

Ken Kato, MD, PhD, of Japan’s National Cancer Center Hospital, discusses the first comprehensive findings on biomarkers from the CheckMate 648 study. These results further corroborate the clinical efficacy of nivolumab plus chemotherapy and nivolumab plus ipilimumab in the first-line treatment of...

gastroesophageal cancer

Long-Term Follow-up of KEYNOTE-590: Benefit of Pembrolizumab Plus Chemotherapy Affirmed in Advanced Esophageal Cancer

Long-term follow-up of the phase III KEYNOTE-590 trial has confirmed the benefit of pembrolizumab plus chemotherapy in advanced esophageal cancer. As compared with chemotherapy alone, after a median follow-up of almost 59 months, patients treated with the chemoimmunotherapy combination were three...

colorectal cancer

First-Line Nivolumab Plus Ipilimumab Shows Benefit in Metastatic Colorectal Cancer Subset

In the phase III CheckMate 8HW trial, previously untreated patients with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) metastatic colorectal cancer derived significant benefit from an immunotherapy doublet of nivolumab plus ipilimumab in the first-line setting, which...

Expert Point of View: Rory M. Shallis, MD

Rory M. Shallis, MD, Assistant Professor of Medicine (Hematology) at Yale School of Medicine, shared his thoughts on the use of revumenib in histone-lysine N-methyltransferase 2A-rearranged (KMT2A-rearranged) leukemia, as reported in the phase II AUGMENT-101 trial. In an interview with The ASCO...

leukemia

AUGMENT-101 Trial: Menin Inhibitor Revumenib Shows Activity in KMT2A-Rearranged Acute Leukemia

In heavily pretreated patients with a challenging type of acute leukemia, the menin inhibitor revumenib demonstrated clinically meaningful activity, including high rates of response and measurable residual disease (MRD) negativity, according to the efficacy and safety results of the phase II...

gastroesophageal cancer

Michael K. Gibson, MD, PhD, on Esophageal Cancer: Expert Commentary on Two Key Studies

Michael K. Gibson, MD, PhD, of Vanderbilt University Medical Center, discusses phase III findings on chemotherapy plus camrelizumab in the ESCORT-NEO trial of patients with resectable esophageal squamous cell carcinoma; and phase III SKYSCRAPER-08 results on first-line tiragolumab plus atezolizumab ...

New Director of the University of Hawaii Cancer Center, Naoto T. Ueno, MD, PhD, FACP, Is Also a Two-Time Cancer Survivor

In this installment of The ASCO Post ’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Naoto T. Ueno, MD, PhD, FACP, Director of the University of Hawaii Cancer Center. Along with his duties leading the cancer center, Dr. Ueno leads translational breast cancer research...

supportive care

Antiemetic Strategies for Patients Receiving Highly Emetogenic Chemotherapy

In an Indian single-center phase III trial reported in The Lancet Oncology, Bajpai et al found that low-dose olanzapine was noninferior to standard-dose olanzapine plus triple antiemetic therapy in terms of antiemetic efficacy and reduced daytime somnolence in patients with solid tumors receiving...

Advertisement

Advertisement




Advertisement